Cancer Research and Treatment

Original Articles

Lung and Thoracic cancer

Predictive Value of Interstitial Lung Abnormalities for Postoperative Pulmonary Complications in Elderly Patients with Early-stage Lung Cancer: Won Gi Jeong, Yun-Hyeon Kim, Jong Eun Lee, In-Jae Oh, Sang Yun Song, Kum Ju Chae, Hye Mi Park; Cancer Res Treat. 2022;54(3):744-752. Published online September 28, 2021; DOI: https://doi.org/10.4143/crt.2021.772

Abstract PDF Supplementary Material PubReader ePub

Purpose
Identifying pretreatment interstitial lung abnormalities (ILAs) is important because of their predictive value for complications after lung cancer treatment. This study aimed to assess the predictive value of ILAs for postoperative pulmonary complications (PPCs) in elderly patients undergoing curative resection for early-stage non-small cell lung cancer (NSCLC).
Materials and Methods
Elderly patients (age ≥ 70 years) who underwent curative resection for pathologic stage I or II NSCLC with normal preoperative spirometry results (pre-bronchodilator forced expiratory volume in 1 s to forced vital capacity [FVC] ratio > 0.70 and FVC ≥ 80% of the predicted value) between January 2012 and December 2019 were retrospectively identified. Univariable and multivariable regression analyses were performed to assess risk factors for PPCs. The Kaplan–Meier method and log-rank test were used to analyze the relationship between ILAs and postoperative mortality. One-way analysis of variance was performed to assess the correlation between ILAs and hospital stay duration.
Results
A total of 262 patients (median age, 73 [interquartile range, 71–76] years; 132 male) were evaluated. A multivariable logistic regression model revealed that, among several relevant risk factors, fibrotic ILAs independently predicted both overall PPCs (adjusted odds ratio [OR], 4.84; 95% confidence interval [CI], 1.35–17.38; p=0.016) and major PPCs (adjusted OR, 8.72; 95% CI, 1.71–44.38; p=0.009). Fibrotic ILAs were significantly associated with higher postoperative mortality and longer hospital stay (F=5.21, p=0.006).
Conclusion
Pretreatment fibrotic ILAs are associated with PPCs, higher postoperative mortality, and longer hospital stay.

Citations

Citations to this article as recorded by

Pretreatment Interstitial Lung Abnormalities Detected on Abdominal Computed Tomography Scans in Prostate Cancer Patients
Hyun Jin Kim, Won Gi Jeong, Jeong Yeop Lee, Hyo-Jae Lee, Byung Chan Lee, Hyo Soon Lim, Yun-Hyeon Kim
Journal of Computer Assisted Tomography.2024; 48(3): 406. CrossRef
Interstitial Lung Abnormalities
Noriaki Wada, Gary M. Hunninghake, Hiroto Hatabu
Clinics in Chest Medicine.2024; 45(2): 433. CrossRef
Incidence and risk factors of pulmonary complications after lung cancer surgery: A systematic review and meta-analysis
Ting Deng, Jiamei Song, Jinmei Tuo, Yu Wang, Jin Li, Lorna Kwai Ping Suen, Yan Liang, Junliang Ma, Shaolin Chen
Heliyon.2024; 10(12): e32821. CrossRef
Survival impact of fibrotic interstitial lung abnormalities in resected stage IA non-small cell lung cancer
Won Gi Jeong, Yun-Hyeon Kim
The British Journal of Radiology.2023;[Epub] CrossRef
Radiologic Progression of Interstitial Lung Abnormalities following Surgical Resection in Patients with Lung Cancer
Yoon Joo Shin, Jeong Geun Yi, Mi Young Kim, Donghee Son, Su Yeon Ahn
Journal of Clinical Medicine.2023; 12(21): 6858. CrossRef
Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
Pengfei Wang, Li Zhang, Qian Guo, Lifen Zhao, Yanyan Hao
Open Medicine.2023;[Epub] CrossRef
Clinical implication of interstitial lung abnormality in elderly patients with early‐stage non‐small cell lung cancer
Seong Woo Cho, Won Gi Jeong, Jong Eun Lee, In‐Jae Oh, Sang Yun Song, Hye Mi Park, Hyo‐Jae Lee, Yun‐Hyeon Kim
Thoracic Cancer.2022; 13(7): 977. CrossRef

6,771 View
165 Download
8 Web of Science
7 Crossref

Palliative Medicine

Safety, Efficacy, and Patient Satisfaction with Initial Peripherally Inserted Central Catheters Compared with Usual Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study: Eun Ju Park, Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, Ki Sun Jung, So Yeon Oh, Yun Jeong Hong, Jin Hyeok Kim, Joo Yeon Jang, Ung-Bae Jeon; Cancer Res Treat. 2021;53(3):881-888. Published online December 22, 2020; DOI: https://doi.org/10.4143/crt.2020.1008

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate whether routine insertion of peripherally inserted central catheter (PICC) at admission to a hospice-palliative care (HPC) unit is acceptable in terms of safety and efficacy and whether it results in superior patient satisfaction compared to usual intravenous (IV) access.
Materials and Methods
Terminally ill cancer patients were randomly assigned to two arms: routine PICC access and usual IV access arm. The primary endpoint was IV maintenance success rate, defined as the rate of functional IV maintenance until the intended time (discharge, transfer, or death).
Results
A total of 66 terminally ill cancer patients were enrolled and randomized to study arms. Among them, 57 patients (routine PICC, 29; usual IV, 28) were analyzed. In the routine PICC arm, mean time to PICC was 0.84 days (range, 0 to 3 days), 27 patients maintained PICC with function until the intended time. In the usual IV arm, 11 patients maintained peripheral IV access until the intended time, and 15 patients underwent PICC insertion. The IV maintenance success rate in the routine PICC arm (27/29, 93.1%) was similar to that in the usual IV arm (26/28, 92.8%, p=0.958). Patient satisfaction at day 5 was better in the routine PICC arm (97%, ‘a little comfort’ or ‘much comfort’) compared with the usual IV arm (21%) (p <0.001).
Conclusion
Routine PICC insertion in terminally ill cancer patients was comparable in safety and efficacy and resulted in superior satisfaction compared with usual IV access. Thus, routine PICC insertion could be considered at admission to the HPC unit.

Citations

Citations to this article as recorded by

Implementation of Tunneled Peripherally Inserted Central Catheters Placement in Cancer Patients: A Randomized Multicenter Study
Yuan Sheng, Li-Hong Yang, Yan Wu, Wei Gao, Sheng-Yi Dongye
Clinical Nursing Research.2024; 33(1): 19. CrossRef
The Use of a High Flow PICC Catheter for Stem Cell and Lymphocyte Apheresis: The Initial Experience of a Pediatric Oncology Center in Brazil
Vilani Kremer, Andréia Rheinheimer, Ana Luiza Rodrigues, Andressa Taborda, Robson Coelho, Antonella Zanette
Journal of Pediatric Surgery.2024; 59(8): 1600. CrossRef
Analysis of Risk Factors for Peripherally Inserted Central Venous Catheter-Associated Bloodstream Infection
Sungho Lee, Kwanhoon Park, Kang Yoon Lee, Dongbeen Choi, Ji Young Jang
Journal of Acute Care Surgery.2024; 14(1): 9. CrossRef
Central venous access device terminologies, complications, and reason for removal in oncology: a scoping review
Kerrie Curtis, Karla Gough, Meinir Krishnasamy, Elena Tarasenko, Geoff Hill, Samantha Keogh
BMC Cancer.2024;[Epub] CrossRef
A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine as Adjuvant to Opioids in Terminally Ill Cancer Patients With Refractory Cancer Pain (CIVIK Trial)
Kwonoh Park, Jae-Joon Kim, Sang-Bo Oh, So Yeon Oh, Yun Jeong Hong, Seo-jun Kim, Eun-Ju Park, Nayeon Choi, Seon-Hi Shin, Sungeun Kim, Heejung Ko
American Journal of Hospice and Palliative Medicine®.2024;[Epub] CrossRef
Use of peripherally inserted central venous catheters and midline catheters for palliative care in patients with cancer: a systematic review
Eva Gravdahl, Dagny Faksvåg Haugen, Olav Magnus Fredheim
Supportive Care in Cancer.2024;[Epub] CrossRef
Machine Learning Predicts Peripherally Inserted Central Catheters-Related Deep Vein Thrombosis Using Patient Features and Catheterization Technology Features
Yuan Sheng, Wei Gao
Clinical Nursing Research.2024; 33(6): 460. CrossRef
Safety of Cryopreserved Stem Cell Infusion through a Peripherally Inserted Central Venous Catheter
Sławomir Milczarek, Piotr Kulig, Alina Zuchmańska, Bartłomiej Baumert, Bogumiła Osękowska, Anna Bielikowicz, Ewa Wilk-Milczarek, Bogusław Machaliński
Cancers.2023; 15(4): 1338. CrossRef
Use and safety of peripherally inserted central catheters and midline catheters in palliative care cancer patients: a retrospective review
Eva Gravdahl, Siri Steine, Knut Magne Augestad, Olav Magnus Fredheim
Supportive Care in Cancer.2023;[Epub] CrossRef
Complications of Central Venous Access Devices Used in Palliative Care Settings for Terminally Ill Cancer Patients: A Systematic Review and Meta-Analysis
Clement Chun-Him Wong, Horace Cheuk-Wai Choi, Victor Ho-Fun Lee
Cancers.2023; 15(19): 4712. CrossRef
Safety and Efficacy of Peripherally Inserted Central Catheter Placement by Surgical Intensivist–Led Vascular Access Team
Byunghyuk Yu, Jihoon Hong
Vascular Specialist International.2022;[Epub] CrossRef
Effects of parenteral nutrition and hydration on survival in advanced cancer patients with malignant bowel obstruction: secondary analysis of a multicenter prospective cohort study
Sayaka Arakawa, Koji Amano, Shunsuke Oyamada, Isseki Maeda, Hiroto Ishiki, Tomofumi Miura, Yutaka Hatano, Akemi Shirado Naito, Mamiko Sato, Tetsuya Ito, Kazuhiro Kosugi, Satoshi Miyake, Tatsuya Morita, Masanori Mori, Satoshi Inoue, Naosuke Yokomichi, Keng
Supportive Care in Cancer.2021; 29(12): 7541. CrossRef
Catheter-related bloodstream infection associated with multiple insertions of the peripherally inserted central catheter in patients with hematological disorders
Yoshinori Hashimoto, Rina Hosoda, Hiromi Omura, Takayuki Tanaka
Scientific Reports.2021;[Epub] CrossRef

6,353 View
199 Download
13 Crossref

Factors Associated with Prolonged Patient-Attributable Delay in the Diagnosis of Colorectal Cancer: Irene Zarcos-Pedrinaci, Teresa Téllez, Francisco Rivas-Ruiz, María del Carmen Padilla-Ruiz, Julia Alcaide, Antonio Rueda, María Luisa Baré, María Manuela Morales Suárez-Varela, Eduardo Briones, Cristina Sarasqueta, Nerea Fernández-Larrea, Antonio Escobar, José María Quintana, Maximino Redondo, REDISSEC-CARESS/CCR group; Cancer Res Treat. 2018;50(4):1270-1280. Published online January 2, 2018; DOI: https://doi.org/10.4143/crt.2017.371

Abstract PDF PubReader ePub

Purpose
The delayed diagnosis of colorectal cancer (CRC) may be attributable to sociodemographic characteristics, to aspects of tumour histopathology or to the functioning of the health system. We seek to determine which of these factors most influences prolonged patient-attributable delay (PPAD) in the diagnosis and treatment of CRC.
Materials and Methods
A prospective, multicentre observational study was conducted in 22 Spanish hospitals. In total, 1,785 patients were recruited to the study between 2010 and 2012 and underwent elective or urgent surgery. PPAD is considered to occur when the time elapsed between a patient presenting the symptom and him/her seeking attention from the primary care physician or hospital emergency department exceeds 180 days. A bivariate analysis was performed to assess differences in variables segmented by tumour location and patient delay. Multivariate logistic regression analysis was performed on the outcome variable, PPAD.
Results
The rate of PPAD among this population was 12.1%. PPAD was significantly associated with altered bowel rhythm (odds ratio [OR], 1.36; 95% confidence interval [CI], 1.02 to 1.83) and with adenocarcinoma histology, in comparison with mucinous adenocarcinoma (OR, 2.03; 95% CI, 1.11 to 3.71). Other sociocultural factors and clinicopathological features were not independent predictors of PPAD.
Conclusion
Many patients do not consider altered bowel rhythm an alarming symptom, warranting a visit to the doctor. PPAD could be reduced by improving health education, raising awareness of CRC-related symptoms.

Citations

Citations to this article as recorded by

Improving colorectal cancer in Alberta, Canada: a qualitative study of patients and close contacts’ perceptions on diagnosis following an emergency department presentation
Anna Pujadas Botey, Ashley J. Watson, Paula J. Robson
BMC Health Services Research.2024;[Epub] CrossRef
Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer
Malin Ljunggren, Caroline E. Weibull, Gabriella Palmer, Emerik Osterlund, Bengt Glimelius, Anna Martling, Caroline Nordenvall
International Journal of Cancer.2023; 152(3): 363. CrossRef
Cancer awareness in older adults: Results from the Spanish Onco-barometer cross-sectional survey
Dafina Petrova, Marina Pollán, Rocio Garcia-Retamero, Miguel Rodríguez-Barranco, Andrés Catena, Lucia Castillo Portellano, Maria-José Sánchez
International Journal of Nursing Studies.2023; 140: 104466. CrossRef
Perceived barriers to early presentation and symptom-specific time to seek medical advice for possible colorectal cancer symptoms among Palestinians
Mohamedraed Elshami, Mohammed Ayyad, Fatma Khader Hamdan, Mohammed Alser, Ibrahim Al-Slaibi, Shoruq Ahmed Naji, Balqees Mustafa Mohamad, Wejdan Sudki Isleem, Adela Shurrab, Bashar Yaghi, Yahya Ayyash Qabaja, Mohammad Fuad Dwikat, Raneen Raed Sweity, Remah
Scientific Reports.2023;[Epub] CrossRef
Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer
María Padilla-Ruiz, María Morales-Suárez-Varela, Francisco Rivas-Ruiz, Julia Alcaide, Esperanza Varela-Moreno, Irene Zarcos-Pedrinaci, Teresa Téllez, Nerea Fernández-de Larrea-Baz, Marisa Baré, Amaia Bilbao, Cristina Sarasqueta, Urko Aguirre-Larracoechea,
International Journal of Environmental Research and Public Health.2022; 19(6): 3626. CrossRef
Patient delay to diagnosis and its predictors among colorectal cancer patients: A cross-sectional study based on the Theory of Planned Behavior
Ying Jin, Mei-Chun Zheng, Xia Yang, Ting-Lan Chen, Jun-E Zhang
European Journal of Oncology Nursing.2022; 60: 102174. CrossRef
Advanced stage presentation and its determinant factors among colorectal cancer patients in Amhara regional state Referral Hospitals, Northwest Ethiopia
Mulugeta Wassie, Debrework Tesgera Beshah, Yenework Mulu Tiruneh, Negar Rezaei
PLOS ONE.2022; 17(10): e0273692. CrossRef
Suppression of LETM1 inhibits the proliferation and stemness of colorectal cancer cells through reactive oxygen species–induced autophagy
Nan Che, Zhaoting Yang, Xingzhe Liu, Mengxuan Li, Ying Feng, Chengye Zhang, Chao Li, Yan Cui, Yanhua Xuan
Journal of Cellular and Molecular Medicine.2021; 25(4): 2110. CrossRef
Assessing Knowledge, Physician Interactions and Patient-Reported Barriers to Colorectal Cancer Screening Among Arab Americans in Dearborn, Michigan
Fatima Saad, Mariam Ayyash, Marwa Ayyash, Nadine Elhage, Iman Ali, Mona Makki, Hiam Hamade, R. Alexander Blackwood
Journal of Community Health.2020; 45(5): 900. CrossRef
Targeting Receptor Kinases in Colorectal Cancer
Marilina García-Aranda, Maximino Redondo
Cancers.2019; 11(4): 433. CrossRef

9,141 View
132 Download
11 Web of Science
10 Crossref

Supporting Low-income Cancer Patients: Recommendations for the Public Financial Aid Program in the Republic of Korea: Hye Sook Min, Hyung Kook Yang, Keeho Park; Cancer Res Treat. 2018;50(4):1074-1083. Published online November 15, 2017; DOI: https://doi.org/10.4143/crt.2017.401

Abstract PDF PubReader ePub

Purpose
As the recent term of “financial toxicity” implies, cancer causes a treatment-related financial harm. Financial Aid Program for Cancer Patient (FAPCP) is a government’s financial support for low-income patients in the Republic of Korea. This study aimed to describe FAPCP applicants’ condition and to investigate factors influencing financial burden, which would provide the basis for implementing a strategy for FAPCP administration.
Materials and Methods
The telephone survey results from 2,700 FAPCP participants were analyzed, including demographic, socioeconomic, and disease characteristics and experiences associated with financial burden and the actions or measures to cope with them.
Results
Overall, 87.6% experienced financial burden more than moderate degree, 39.2% got financial help/a loan, 17.8% disposed of their property, and 10.2% changed or stopped treatment owing to medical costs. Monthly household income was connected to financial burden, and the highest income group was associated with the lowest financial burden (odds ratio [OR], 0.21; 95% confidence interval [CI], 0.11 to 0.38) and the lowest rate of changing/stopping care (OR, 0.23; 95% CI, 0.05 to 1.00). Parents of childhood cancer patients got financial help/a loan (OR, 2.24; 95% CI, 1.03 to 4.88) and disposed of their property (OR, 3.18; 95% CI, 1.40 to 7.22) more frequently, and Medical Aids applicants showed the highest rate of changing/stopping care (OR, 3.01; 95% CI, 1.89 to 4.78).
Conclusion
FAPCP targets low income groups; however, financial burden and the consequent actions taken still exist disproportionately, depending on the income of the applicants. FAPCP should focus on more vulnerable groups including Medical Aid applicants and parents of childhood cancer patients, by increasing funds and expanding their support coverage.

Citations

Citations to this article as recorded by

Identifying the factors affecting financial toxicity status in patients with middle and advanced colorectal cancer: a cross-sectional study
Xiaofang He, Jie Chen, Lin Zhang, Qiuping Li, Xiaoli Zhu, Jie Zhao, Ying Chen
Frontiers in Public Health.2024;[Epub] CrossRef
Individual and joint effect of socioeconomic status and lifestyle factors on cancer in Korea
Chi Lan Tran, Kui Son Choi, Sun‐Young Kim, Jin‐Kyoung Oh
Cancer Medicine.2023; 12(16): 17389. CrossRef
Financial hardship in families of children or adolescents with cancer: a systematic literature review
Julie Ritter, Savannah Allen, Phillip D Cohen, Andrés Felipe Fajardo, Kelsey Marx, Patrícia Loggetto, Carmen Auste, Hedley Lewis, Karla Emília de Sá Rodrigues, Sharmeen Hussain, Ayomide Omotola, Nancy S Bolous, Harsha Thirumurthy, Beverley M Essue, Eva St
The Lancet Oncology.2023; 24(9): e364. CrossRef
Trends in medical care utilization in patients with cancer: An analysis of real‐world data in a tertiary hospital in Korea, 2014–2019
Jung‐Hyun Won, Tae Kyu Chung, Joochul Lee, Sangwon Yoon, Yoomin Jeon, Howard Lee
Cancer Medicine.2023; 12(22): 21022. CrossRef
Impact of objective financial burden and subjective financial distress on spiritual well-being and quality of life among working-age cancer survivors
Danbee Kang, Ka Ryeong Bae, Jihyun Lim, Nayeon Kim, Sungkeun Shim, Sun Seog Kweon, Hwa Jeong Seo, Juhee Cho
Supportive Care in Cancer.2022; 30(6): 4917. CrossRef
The influence of cross-regional medical treatment on total medical expenses, medical insurance payments, and out-of-pocket expenses of patients with malignant tumors in Chinese low-income areas
Bokai Zhang, Haixin Wang, Hongyu Zhang, Guomei Tian, Ting Zhang, Qi Shi, Jian Liu, Jinpeng Xu, Jingchu Liu, Qunhong Wu, Zheng Kang
Cost Effectiveness and Resource Allocation.2022;[Epub] CrossRef
Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems
Divya A. Parikh, Meera Ragavan, Ritika Dutta, Jeffrey Garnet Edwards, James Dickerson, Debeshi Maitra, Sangeeta Aggarwal, Fa-Chyi Lee, Manali I. Patel
JCO Oncology Practice.2021; 17(10): e1450. CrossRef
Burden of Treatment among Elderly Patients with Cancer: A Scoping Review
Adem Sav, Sara S. McMillan, Adeola Akosile
Healthcare.2021; 9(5): 612. CrossRef
Symptom experiences and health‐related quality of life among non‐small cell lung cancer patients participating in clinical trials
Kyunghwa Lee, Eui Geum Oh, Sanghee Kim, Sang‐We Kim
Journal of Clinical Nursing.2019; 28(11-12): 2111. CrossRef
The Incidences and Characteristics of Various Cancers in Patients on Dialysis: a Korean Nationwide Study
Soon Kil Kwon, Joung-Ho Han, Hye-Young Kim, Gilwon Kang, Minseok Kang, Yeonkook J. Kim, Jinsoo Min
Journal of Korean Medical Science.2019;[Epub] CrossRef
Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment
Won-Il Choi, Jiah Choi, Mi-Ae Kim, Gyumin Lee, Jihyeon Jeong, Choong Won Lee
Cancer Research and Treatment.2019; 51(3): 1241. CrossRef

7,388 View
130 Download
11 Web of Science
11 Crossref

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate: Yoojoo Lim, Jee Min Lim, Won Jae Jeong, Kyung-Hun Lee, Bhumsuk Keam, Tae-Yong Kim, Tae Min Kim, Sae-Won Han, Do Youn Oh, Dong-Wan Kim, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Seock-Ah Im; Cancer Res Treat. 2017;49(4):1033-1043. Published online April 7, 2017; DOI: https://doi.org/10.4143/crt.2016.413

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to assess current levels of awareness of clinical trials (CTs), perceptions regarding their benefits and willingness to participate to CTs among Korean cancer patients.
Materials and Methods
From December 2012 to August 2015, we distributed questionnaires to cancer patients receiving systemic anti-cancer therapy at Seoul National University Hospital, Seoul, Korea.
Results
A total of 397 out of 520 requested patients (76.3%) responded to the survey. Among the 397 patients, 62.5% were female and the median age was 52 years. Overall, 97.4% (387/397) answered that they have at least heard of CTs. When asked about their level of awareness, 23.8% (92/387) answered that they could more than roughly explain about CTs. The average visual analogue scale score of CT benefit in all patients was 6.43 (standard deviation, 2.20). Patients who were only familiar with the term without detailed knowledge of the contents had the least expectation of benefit from CTs (p=0.015). When asked about their willingness to participate in CTs, 56.7% (225/397) answered positively. Patients with higher levels of awareness of CTs showed higher willingness to participate (p < 0.001). Heavily treated patients and patients with previous experience regarding CTs also showed a higher willingness to participate (p < 0.001). The perceived benefit of CTs was higher in the group willing to participate (p=0.026).
Conclusion
The patient’s level of awareness regarding CTs was positively related to the positive perception and willingness to participate. Although the general awareness of CTs was high, a relatively large proportion of patients did not have accurate knowledge; therefore, proper and accurate patient education is necessary.

Citations

Citations to this article as recorded by

Depression and anxiety among hemophilia patients enrolled in clinical trials: a multi-center cohort study
Zhen Peng, Xiaoyu Zhu, Chongwei Wang, Mingfeng Zhou, Xiaoling Xu, Yin Chen
Annals of Hematology.2023; 102(7): 1927. CrossRef
Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events
Zhen Peng, Chongwei Wang, Yubei Sun, Yan Ma, Jumei Wang, Fei Xu, Xiaoling Xu, Yin Chen
Cancer Medicine.2023; 12(19): 20015. CrossRef
Acceptance Factors and Psychological Investigation of Clinical Trials in Cancer Patients
Jiangjie Sun, Jingyi Fang, Chenchen Zhang, Nannan Jia, Weiming Zhao, Jinjian Gao, Yingying Huang, Jiqing Hao, Liping Zhang, Carmen M Galvez-Sánchez
Behavioural Neurology.2023; 2023: 1. CrossRef
Understanding and attitudes of the Jordanian public about clinical research ethics
Mera A Ababneh, Sayer I Al-Azzam, Karem Alzoubi, Abeer Rababa’h, Saddam Al Demour
Research Ethics.2021; 17(2): 228. CrossRef
A patient-focused, theory-guided approach to survey design identified barriers to and drivers of clinical trial participation
Jamie C. Brehaut, Kelly Carroll, Justin Presseau, Dawn P. Richards, Jenn Gordon, Angèle Bénard, Natasha Hudek, Ian D. Graham, Dean A. Fergusson, Susan Marlin
Journal of Clinical Epidemiology.2021; 132: 106. CrossRef
Awareness of breast cancer patients in Poland about clinical trials as available treatment options
Mikołaj Bartoszkiewicz, Joanna Kufel-Grabowska, Maria Litwiniuk
Breast Disease.2021; 40(1): 33. CrossRef
Results from a Theory-Guided Survey to Support Breast Cancer Trial Participation: Barriers, Enablers, and What to Do about them
Jamie C. Brehaut, Kelly Carroll, Jenn Gordon, Justin Presseau, Dawn P. Richards, Dean A. Fergusson, Ian D. Graham, Susan Marlin
Current Oncology.2021; 28(3): 2014. CrossRef
Regional Differences in Access to Clinical Trials for Cancer in Korea
Woorim Kim, Seongkyeong Jang, Yoon Jung Chang
Quality Improvement in Health Care.2021; 27(1): 20. CrossRef
How Cancer Patients Perceive Clinical Trials (CTs) in the Era of CTs: Current Perception and Its Differences Between Common and Rare Cancers
Ji Hyun Park, Ji Sung Lee, HaYeong Koo, Jeong Eun Kim, Jin-Hee Ahn, Min-Hee Ryu, Sook-ryun Park, Shin-kyo Yoon, Jae Cheol Lee, Yong-Sang Hong, Sun Young Kim, Kyo-Pyo Kim, Chang-Hoon Yoo, Jung Yong Hong, Jae Lyun Lee, Kyung Hae Jung, Baek-Yeol Rhyoo, Tae W
Journal of Cancer Education.2020; 35(3): 545. CrossRef
Colorectal cancer survivors’ willingness to participate in a hypothetical clinical trial of Korean medicine: A cross-sectional study
Yown Hwangbo, Gyung Mo Son, Kyung Hee Kim, Myeong Sook Kwon, Kun Hyung Kim
European Journal of Integrative Medicine.2020; 33: 101033. CrossRef
Perception and Satisfaction of Anticancer Drug Clinical Trials in Cancer Patients
Ju Kyung Jeon, Jeong Hye Kim
Asian Oncology Nursing.2019; 19(1): 18. CrossRef
Challenges in informed consent decision-making in Korean clinical research: A participant perspective
Im-Soon Choi, Eun Young Choi, Iyn-Hyang Lee, Dermot Cox
PLOS ONE.2019; 14(5): e0216889. CrossRef
Clinical Trials: What, Where, When?
Olga S. Kobyakova, Ivan A. Deev, Evgeny S. Kulikov, Roman I. Shtykh, Igor D. Pimenov, Olga I. Zvonareva, Igor V. Mareev
Annals of the Russian academy of medical sciences.2018; 73(5): 314. CrossRef

8,381 View
179 Download
11 Web of Science
13 Crossref

Special Article

Development of a Community-Based Palliative Care Model for Advance Cancer Patients in Public Health Centers in Busan, Korea: Sook-Nam Kim, Soon-Ock Choi, Seong Hoon Shin, Ji-Sun Ryu, Jeong-Won Baik; Cancer Res Treat. 2017;49(3):559-568. Published online October 18, 2016; DOI: https://doi.org/10.4143/crt.2016.276

Abstract PDF PubReader ePub

Purpose
A feasible palliative care model for advance cancer patients is needed in Korea with its rapidly aging population and corresponding increase in cancer prevalence. This study describes the process involved in the development of a community-based palliative care (CBPC) model implemented originally in a Busan pilot project.
Materials and Methods
The model development included steps I and II of the pilot project, identification of the service types, a survey exploring the community demand for palliative care, construction of an operational infrastructure, and the establishment of a service delivery system. Public health centers (including Busan regional cancer centers, palliative care centers, and social welfare centers) served as the regional hubs in the development of a palliative care model.
Results
The palliative care project included the provision of palliative care, establishment of a support system for the operations, improvement of personnel capacity, development of an educational and promotional program, and the establishment of an assessment system to improve quality. The operational infrastructure included a service management team, provision teams, and a support team. The Busan Metropolitan City CBPC model was based on the principles of palliative care as well as the characteristics of public health centers that implemented the community health projects.
Conclusion
The potential use of the Busan CBPC model in Korea should be explored further through service evaluations.

Citations

Citations to this article as recorded by

Palliative Care for Cancer Patients in Asia: Challenges and Countermeasures
Yu Wang, Xinqing Zhang, Yilin Huang, Xiangyu Ma
Oncology Reviews.2024;[Epub] CrossRef
The contribution of the nursing profession to the establishment of social justice: A grounded theory study
Fariba Hosseinzadegan, Hosein Habibzadeh, Madineh Jasemi
Nursing Ethics.2024; 31(5): 759. CrossRef
Exploring caregivers’ perceptions of community-based service requirements of patients with spinal cord injury: a qualitative study
Nasrin Galehdar, Heshmatolah Heydari
BMC Primary Care.2023;[Epub] CrossRef
Perception about Home Visiting Hospice Service of End of Life Patients at Home
So Young Kim
Journal of Korean Association for Qualitative Research.2023; 8(2): 153. CrossRef
A Review of Palliative Care Service Delivery Models and Patient Outcomes for Adults with Cancer in Selected East and Southeast Asian Countries
Chun-Yi Tseng, Natalia Calanzani
International Journal of Medical Students.2023; 11(4): 294. CrossRef
Developing an integrated model of community-based palliative care into the primary health care (PHC) for terminally ill cancer patients in Iran
Suzanne Hojjat-Assari, Maryam Rassouli, Maxwell Madani, Heshmatolah Heydari
BMC Palliative Care.2021;[Epub] CrossRef
Structure and process of palliative care provision: a nationwide study of public hospitals in Thailand
Parichat Dokmai, Natthani Meemon, Seung Chun Paek, Supakarn Tayjasanant
BMC Health Services Research.2021;[Epub] CrossRef
Community Care for Cancer Patients in Rural Areas: An Integrated Regional Cancer Center and Public Health Center Partnership Model
Jung Hun Kang, Chang Yoon Jung, Ki-Soo Park, Jung Sik Huh, Sung Yong Oh, Jung Hye Kwon
The Korean Journal of Hospice and Palliative Care.2021; 24(4): 226. CrossRef
Differences in medical costs for end-of-life patients receiving traditional care and those receiving hospice care: A retrospective study
Ya-Ting Huang, Ying-Wei Wang, Chou-Wen Chi, Wen-Yu Hu, Rung Lin, Chih-Chung Shiao, Woung-Ru Tang, Chun Chieh Yeh
PLOS ONE.2020; 15(2): e0229176. CrossRef
Exploring health care providers’ perceptions about home-based palliative care in terminally ill cancer patients
Heshmatolah Heydari, Suzanne Hojjat-Assari, Mohammad Almasian, Pooneh Pirjani
BMC Palliative Care.2019;[Epub] CrossRef
Structural Analysis on Quality of Life for Terminal Cancer Patients provided Hospice and Palliative Care Services in Community Health Centers
Sook-Nam Kim, Soon-Ock Choi, Ji-Seon Ryu, Jung-Rim Kim
The Korean Journal of Health Service Management.2019; 13(4): 163. CrossRef
Evaluation of Outcomes of the Busan Community-based Palliative Care Project in Korea
Soon-Ock Choi, Sook-Nam Kim, Seong-Hoon Shin, Ji-Seon Ryu, Jeong-Won Baik, Jung-Rim Kim, Nae-Hyeon Kim
Asian Nursing Research.2018; 12(4): 286. CrossRef

10,717 View
378 Download
11 Web of Science
12 Crossref

Original Articles

Psychosocial Impact of Cancer Patients on Their Family Members: Sun Min Lim, Hyeon Chang Kim, Soohyeon Lee; Cancer Res Treat. 2013;45(3):226-233. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.226

Abstract PDF PubReader ePub

PURPOSE
A population-based study was conducted in order to examine the characteristics of family members of cancer patients in comparison with the general population and also to evaluate the psychosocial impact of cancer patients on their family members.
MATERIALS AND METHODS
From the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) (2007-2009) dataset, we identified 460 cancer patients and then selected family members of these patients who were aged 20 years or older (n=565). The control group was sampled from members of families without a cancer patient with matching for sex and age (n=2,260). Serial conditional logistic regression models were used for comparison of characteristics between family members of cancer patients and subjects in the control group.
RESULTS
Family members of cancer patients were less employed (57.9% vs. 63.0%, p<0.001), more functionally limited (20.2% vs. 16.5%, p=0.032), and had lower self-rated health (p=0.023) compared with sex and age-matched control subjects. They also had a significantly higher level of stress (79.7% vs. 76.1%, p=0.008), history of depression (12.9% vs. 10.2%, p=0.035), and current depressive symptoms (5.5% vs. 3.5%, p=0.038). However, higher physical activity was reported in family members of cancer patients (13.6% vs. 9.6%, p=0.003) than in control subjects. The presence of a cancer patient in the family showed an association with current depressive symptoms (odds ratio, 1.62; 95% confidence interval, 1.05 to 2.48; p=0.028), however, the association was no longer significant after adjustment for household income, education level, and employment status (p=0.304).
CONCLUSION
Family members of cancer patients are more susceptible to depression, probably due to adverse change in socioeconomic status. Use of multidisciplinary approaches for promotion of psychological health and well-being is essential.

Citations

Citations to this article as recorded by

Pediatric cancers and family financial toxicity in the Philippines: insights for Southeast Asia and similarly resourced settings
Rod Carlo Columbres, Erin Jay G. Feliciano, Kathleen Joy Taleon-Tampo, Katelyn Edelwina Y. Legaspi, Michelle Ann B. Eala, Kenrick Ng, Fumiko Chino, Frederic Ivan L. Ting, Edward Christopher Dee
The Lancet Regional Health - Western Pacific.2024; 47: 101114. CrossRef
Financial Sequelae of Cancer for Patients' Family Members and Caregivers: A Focus on the Philippines
Rod Carlo Columbres, Erin Jay G. Feliciano, Lance Isidore Catedral, Jose Ma. H. Zaldarriaga, Michelle Ann B. Eala, Jerickson Abbie Flores, Enrico D. Tangco, Narjust Florez, Frederic Ivan L. Ting, Edward Christopher Dee
JCO Global Oncology.2024;[Epub] CrossRef
Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report
Jean-François Stephan, Sani Karam
Journal of Palliative Medicine.2024;[Epub] CrossRef
Benefits of Spiritual and Religious Support in the Pain Management of Cancer Patients: A Literature Scoping Review
Iago Dillion Lima Cavalcanti, Diogo Timóteo Costa, José Cleberson Santos Soares, Mariane Cajubá de Britto Lira Nogueira
Journal of Religion and Health.2023; 62(3): 1998. CrossRef
Association between changes in having of cancer patients in the family and depression: A longitudinal panel study
Yun Seo Jang, Na-Young Yoon, Kyungduk Hurh, Eun-Cheol Park, Min Jin Ha
Journal of Affective Disorders.2023; 333: 482. CrossRef
Cultural adaptation of meaning-centered psychotherapy for latino families: a protocol
Normarie Torres Blasco, Rosario Costas Muñiz, Carolina Zamore, Laura Porter, Maria Claros, Guillermo Bernal, Megan Johnson Shen, William Breitbart, EM Castro
BMJ Open.2022; 12(4): e045487. CrossRef
Unmet supportive care needs of caregivers according to medical settings of cancer patients: a cross-sectional study
Véronique Christophe, Amelie Anota, Laurence Vanlemmens, Alexis Cortot, Tatiana Ceban, Guillaume Piessen, Emilie Charton, Anne-Sophie Baudry
Supportive Care in Cancer.2022; 30(11): 9411. CrossRef
Information Received and Usefulness of the Sources of Information to Cancer Patients at a Tertiary Care Centre in Malaysia
Yie Lin Lew, Fuad Ismail, Siti Azdiah Abdul Aziz, Noraida Mohamed Shah
Journal of Cancer Education.2021; 36(2): 350. CrossRef
Breaking News of Cancer Diagnosis: A Qualitative Study on the Experiences and Emotional Needs of Patients With Cancer in a Multiethnic Asian Setting
Li-Ping Wong, Yek-Ching Kong, Nanthini Thevi Bhoo-Pathy, Shridevi Subramaniam, Ros Suzanna Bustamam, Nur Aishah Taib, Gwo-Fuang Ho, Hafizah Zaharah, Matin Mellor, Yin-Ling Woo, Cheng-Har Yip, Nirmala Bhoo-Pathy
JCO Oncology Practice.2021; 17(4): e548. CrossRef
Mood Disorder in Cancer Patients Undergoing Radiotherapy During the COVID-19 Outbreak
Valerio Nardone, Alfonso Reginelli, Claudia Vinciguerra, Pierpaolo Correale, Maria Grazia Calvanese, Sara Falivene, Angelo Sangiovanni, Roberta Grassi, Angela Di Biase, Maria Angela Polifrone, Michele Caraglia, Salvatore Cappabianca, Cesare Guida
Frontiers in Psychology.2021;[Epub] CrossRef
Therapeutic Advances in the Management of Smoldering Myeloma
Rafiullah Khan, Umar Zahid, Vidya Kollu, Nusrat Jahan, McBride Ali, Guido Tricot, Faiz Anwer
American Journal of Therapeutics.2020; 27(2): e194. CrossRef
Music therapy and radiation oncology: State of art and future directions
Valerio Nardone, Claudia Vinciguerra, Pierpaolo Correale, Cesare Guida, Paolo Tini, Alfonso Reginelli, Salvatore Cappabianca
Complementary Therapies in Clinical Practice.2020; 39: 101124. CrossRef
Supportive care needs: An aspect of Thai women with breast cancer undergoing chemotherapy
Supanee Klungrit, Sureeporn Thanasilp, Chanokporn Jitpanya
European Journal of Oncology Nursing.2019; 41: 82. CrossRef
Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology
Anne-Sophie Baudry, Laurence Vanlemmens, Amelie Anota, Alexis Cortot, Guillaume Piessen, Veronique Christophe
European Journal of Oncology Nursing.2019; 43: 101669. CrossRef
Evidence-based feedback about emotional cancer challenges experienced in South Africa: A qualitative analysis of 316 photovoice interviews
Lynn Barbara Edwards, Linda Estelle Greeff
Global Public Health.2018; 13(10): 1409. CrossRef
Family Members of Cancer Patients in Korea Are at an Increased Risk of Medically Diagnosed Depression
Youngdae Cho, Yongwoo Jeon, Sung-In Jang, Eun-Cheol Park
Journal of Preventive Medicine and Public Health.2018; 51(2): 100. CrossRef
Stress and Depressive Symptoms in Cancer Survivors and Their Family Members: Korea Community Health Survey, 2012
Mi Han
International Journal of Environmental Research and Public Health.2017; 14(9): 999. CrossRef
Psychological Status and Associated Factors among Korean Cancer Survivors: a Cross-Sectional Analysis of the Fourth & Fifth Korea National Health and Nutrition Examination Surveys
Kyung-Hyun Choi, Sang Min Park
Journal of Korean Medical Science.2016; 31(7): 1105. CrossRef
Experiential Group Work for Cancer Patients Shaped by Experiences of Participants During Group Intervention
Joan Nee Wey Khng, Ivan Mun Hong Woo, Gilbert Fan
Future Oncology.2016; 12(24): 2817. CrossRef
High-risk smoldering myeloma: Perspective on watchful monitoring
Siyang Leng, Suzanne Lentzsch
Seminars in Oncology.2016; 43(6): 697. CrossRef

11,127 View
106 Download
20 Crossref

The Increasing Frequency of Cervical Cancer in Korean Women under 35: Chan Hee Han, Hyun Jung Cho, Sung Jong Lee, Jeong Hoon Bae, Seog Nyen Bae, Sung Eun Namkoong, Jong Sup Park; Cancer Res Treat. 2008;40(1):1-5. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.1

Abstract PDF PubReader ePub

Purpose

The goal of this study was to determine the clinical and epidemiological trends of cervical cancer in young Korean women. Social behavior including sexual habits has changed in Korean women, with sexual activity commencing at a younger age. These changes are likely to influence certain risk factors of cervical cancer, resulting in changing trends in the occurrence of the disease.

Materials and Methods

The incidence of cervical cancer in women less than 35 years-old between January 1990 and December 2006 was analyzed, and available medical records from January 1996 to December 2006 were reviewed. The clinical, pathological and epidemiologic characteristics and changing trends among these young patients were analyzed.

Results

Over the last two decades, the incidence of young (< 35 years) cervical cancer patients increased, more patients had an aggressive form of the disease, and there was a higher rate of women with more advanced education. Human papillomavirus (HPV) infection was detected in 94.0% of the women (63/67) tested. HPV 16 (82.5%) and HPV 18 (12.7%) were the two most common viral infections detected throughout the study period.

Conclusions

The changing trends and risk factors identified suggest a need for more active education of young women about cervical cancer prevention strategies. In addition, young women are strongly recommended to undergo a regular screening test and HPV vaccination.

Citations

Citations to this article as recorded by

Prevalence and Treatment of Vulvar Cancer From 2014−2018: A Nationwide Population-Based Study in Korea
Yung-Taek Ouh, Dongwoo Kang, Hoseob Kim, Jae Kwan Lee, Jin Hwa Hong
Journal of Korean Medical Science.2022;[Epub] CrossRef
Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer
Hosam A Alghanmi
Cureus.2022;[Epub] CrossRef
WITHDRAWN: Polymerase chain reaction technique for molecular detection of HPV16 infections among women with cervical cancer in Dhi-Qar Province
Abduladheem Turki Jalil, Ali Hussein Demin Al-Khafaji, Aleksandr Karevskiy, Saja Hussain Dilfy, Zaman K. Hanan
Materials Today: Proceedings.2021;[Epub] CrossRef
Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview
Min-A Kim, Gwan Hee Han, Jae-Hoon Kim, Kyung Seo
Journal of Korean Medical Science.2018;[Epub] CrossRef
Management for locally advanced cervical cancer: new trends and controversial issues
Oyeon Cho, Mison Chun
Radiation Oncology Journal.2018; 36(4): 254. CrossRef
Trends and Age-Period-Cohort Effects on the Incidence and Mortality Rate of Cervical Cancer in Korea
Eun-Kyeong Moon, Chang-Mo Oh, Young-Joo Won, Jong-Keun Lee, Kyu-Won Jung, Hyunsoon Cho, Jae Kwan Jun, Myong Cheol Lim, Moran Ki
Cancer Research and Treatment.2017; 49(2): 526. CrossRef
Factors associated with participation in cervical cancer screening among young Koreans: a nationwide cross-sectional study
Ha Kyun Chang, Jun-Pyo Myong, Seung Won Byun, Sung-Jong Lee, Yong Seok Lee, Hae-Nam Lee, Keun Ho Lee, Dong Choon Park, Chan Joo Kim, Soo Young Hur, Jong Sup Park, Tae Chul Park
BMJ Open.2017; 7(4): e013868. CrossRef
Molecular Detection and Typing of Human Papillomaviruses in Paraffin-Embedded Cervical Cancer and Pre-Cancer Tissue Specimens
Pezhman Mahmoodi, Hossein Motamedi, Masoud Reza Seyfi Abad Shapouri, Mahjabin Bahrami Shehni, Mohammad Kargar
Iranian Journal of Cancer Prevention.2016;[Epub] CrossRef
Cervical cancer in north-eastern Libya: 2000–2008
F. Ben Khaial, Z. Bodalal, A. Elramli, F. Elkhwsky, A. Eltaguri, R. Bendardaf
Journal of Obstetrics and Gynaecology.2014; 34(6): 523. CrossRef
Current status of the National Cancer Screening Program for cervical cancer in Korea, 2009
Young Hwa Lee, Kui Son Choi, Hoo-Yeon Lee, Jae Kwan Jun
Journal of Gynecologic Oncology.2012; 23(1): 16. CrossRef
Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study
J.-H. Nam, J.-Y. Park, D.-Y. Kim, J.-H. Kim, Y.-M. Kim, Y.-T. Kim
Annals of Oncology.2012; 23(4): 903. CrossRef
The safety of conization in the management of adenocarcinomain situof the uterine cervix
Mi-La Kim, Ho-Suap Hahn, Kyung-Taek Lim, Ki-Heon Lee, Hy-Sook Kim, Sung-Ran Hong, Tae-Jin Kim
Journal of Gynecologic Oncology.2011; 22(1): 25. CrossRef
Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
Seung Cheol Kim, Yong Sang Song, Young-Tae Kim, Young Tak Kim, Ki-Sung Ryu, Bhavyashree Gunapalaiah, Dan Bi, Hans L Bock, Jong-Sup Park
Journal of Gynecologic Oncology.2011; 22(2): 67. CrossRef
Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer
Hyun Hoon Chung, Jae Weon Kim, Kyung Hee Han, Jae Seon Eo, Keon Wook Kang, Noh-Hyun Park, Yong-Sang Song, June-Key Chung, Soon-Beom Kang
Gynecologic Oncology.2011; 120(2): 270. CrossRef

12,726 View
130 Download
14 Crossref

An Evaluation of Nutrition Support for Terminal Cancer Patients at Teaching Hospitals in Korea: Do Yeun Kim, Sang Min Lee, Kyoung Eun Lee, Hye Ran Lee, Jee Hyun Kim, Keun-Wook Lee, Jong Seok Lee, Soon Nam Lee; Cancer Res Treat. 2006;38(4):214-217. Published online December 31, 2006; DOI: https://doi.org/10.4143/crt.2006.38.4.214

Abstract PDF PubReader ePub

Purpose

We wanted to analyze the use of nutrition support for terminal cancer patients, the effect of discussing withdrawal of nutrition support and do-not-resuscitate (DNR) consent on the use of intravenous nutrition during the patient's last week of life and at the time of death.

Materials and Methods

The study involved 362 patients with terminal cancer from four teaching hospitals, and they all died between January 1 2003 and December 31 2005. The basic demographic data, the use of intravenous nutrition during the patient's last week of life and at death, discussion of terminal nutrition withdrawal and DNR consent were evaluated.

Results

In the week before death, the patients received artificial nutrition such as total parenteral nutrition (31%), intravenous albumin infusion (25%), and feeding tube placements (9%). A discussion concerning withdrawal of nutrition support was limited to 25 (7%) patients. DNR consent was obtained from 294 (81%) patients. None of the patients were directly involved in any of these decisions. The discussion about withdrawal of terminal nutrition and DNR consent with the patient's surrogates did not have any effect on reducing the use of parenteral nutrition.

Conclusion

The majority of patients dying of terminal cancer were still given potentially futile nutritional support. Modern clinical guidelines and ethical education about nutritional support at the end of life care is urgently needed in Korean medical practice to provide proper administration of terminal nutrition for end of life care.

Citations

Citations to this article as recorded by

Report of the Lancet Commission on the Value of Death: bringing death back into life
Libby Sallnow, Richard Smith, Sam H Ahmedzai, Afsan Bhadelia, Charlotte Chamberlain, Yali Cong, Brett Doble, Luckson Dullie, Robin Durie, Eric A Finkelstein, Sam Guglani, Melanie Hodson, Bettina S Husebø, Allan Kellehear, Celia Kitzinger, Felicia Marie Kn
The Lancet.2022; 399(10327): 837. CrossRef
A National Study of Life-Sustaining Treatments in South Korea: What Factors Affect Decision-Making?
So-Youn Park, Bomyee Lee, Jeong Yeon Seon, In-Hwan Oh
Cancer Research and Treatment.2021; 53(2): 593. CrossRef
The Trend of Aggressive Treatments in End-of-Life Care for Older People With Dementia After a Policy Change in Taiwan
Ying Hsin Hsu, Ming Yueh Chou, Hsiu-Min Chen, Wei-Cheng Chang, Che Sheng Chu, Yu-Chun Wang, Chiao-Lin Hsu, Chih-Kuang Liang, Ching-Chih Lee, Yu Te Lin
Journal of the American Medical Directors Association.2020; 21(6): 858. CrossRef
Implication of the Life-Sustaining Treatment Decisions Act on End-of-Life Care for Korean Terminal Patients
Jung Sun Kim, Shin Hye Yoo, Wonho Choi, Yejin Kim, Jinui Hong, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
Cancer Research and Treatment.2020; 52(3): 917. CrossRef
Nutrition Intervention through Interdisciplinary Medical Treatment in Hospice Patients: From Admission to Death
Hyelim Kang, Yu Jin Yang, Juyeon Park, Gyu Jin Heo, Jeong-Im Hong, Hye-Jin Kim
Clinical Nutrition Research.2018; 7(2): 146. CrossRef
Evidence for overuse of medical services around the world
Shannon Brownlee, Kalipso Chalkidou, Jenny Doust, Adam G Elshaug, Paul Glasziou, Iona Heath, Somil Nagpal, Vikas Saini, Divya Srivastava, Kelsey Chalmers, Deborah Korenstein
The Lancet.2017; 390(10090): 156. CrossRef
A Randomized Phase II Study To Assess the Effectiveness of Fluid Therapy or Intensive Nutritional Support on Survival in Patients with Advanced Cancer Who Cannot be Nourished via Enteral Route
So Yeon Oh, Hyun Jung Jun, Sung Jae Park, In Ki Park, Ga Jin Lim, Yeonsil Yu, Sung-Ja Cho, Aeran Song
Journal of Palliative Medicine.2014; 17(11): 1266. CrossRef
Evaluation of parenteral nutritional support in the surgical and medical wards of a referral teaching hospital
Samaneh Bairami, Sepideh Elyasi, Hossein Khalili, Saeed Reza Jamali-Moghadam
DARU Journal of Pharmaceutical Sciences.2012;[Epub] CrossRef
Awareness and Attitude Change after End-of-Life Care Education for Medical Students
Hyun Kyung Kim, Eunmi Nam, Kyoung Eun Lee, Soon Nam Lee
The Korean Journal of Hospice and Palliative Care.2012; 15(1): 30. CrossRef
Charactersitics and issues of guideline to withdrawal of a life-sustaining therapy
Younsuck Koh, Dae-Seog Heo, Young Ho Yun, Jeong-Lim Moon, Hyoung Wook Park, Ji Tae Choung, Hyo Sung Jung, Bark Jang Byun, Yoon-Seong Lee
Journal of the Korean Medical Association.2011; 54(7): 747. CrossRef
Nasogastric feeding at the end of life: A virtue ethics approach
Lalit Krishna
Nursing Ethics.2011; 18(4): 485. CrossRef
Chinese Familial Tradition and Western Influence: A Case Study in Singapore on Decision Making at the End of Life
Zheng Jie Marc Ho, Lalit Kumar Radha Krishna, Chung Pheng Alethea Yee
Journal of Pain and Symptom Management.2010; 40(6): 932. CrossRef

10,012 View
71 Download
12 Crossref

Phase 1b Clinical Trial and Pharmacokinetic Evaluation of Recombinant Human Granulocyte - Macrophage Colony: Jae Kyung Roh, Jin Hyuk Choi, Hyung Keun Roh, Sun Young Rha, Kyung Hee Lee, Hye Ran Lee, Jee Sook Hahn, Pum Soo Kim, Byung Soo Kim; J Korean Cancer Assoc. 1994;26(3):495-510.

Abstract PDF: To define the clinical safeties and hematologic effects of subcutaneously administered yeast- derived recombinant human granulocyte-macrophage colony stimulatina factor(rh GM-CSF, LBD-005h and to determine the maximally tolerated dose(MTD) and the pharmacokinetics. Sngle arm open non-randomized phase Ib study was carried in 15 cancer patients#(14 patients evaluable) with chemotherapy induced bone marrow depression. Rh GM-CSF by once-daily subcutaneous administration to groups of 3-6 patients at doses of 50, 100, 150, 250, 350, 500, 700 ug/m/d for 10 consecutive days was escalated unless greater than WHO grade III toxicites were observed. Intrapatient dose escalation was permitted. Clinical safeties and toxicities were observed with frequent hematologic monitering. Blood and urine were collected on day 1, and 8 of rh GM-CSF administration to evaluate the parmacokinetic parameters. Of the 15 enrolled patients, 14 patients were evaluable. Male to female ratio was 8: 6 with median age 32 y-o(10~70 y-o). Seven patients had osteosarcoma, 2 malignant lymphoma, 2 gastric carcinoma, 2 lung cancer and 1 had uterine leiomyosarcoma. The total administered cycles of rh GM-CSF were 24. At each dose step, 3 patients were treated with exception of 6 patients at 500 ug/m/d dose. At all the doses administered, fever and flue-like syndrome were common side effects. Grade I fever and flue-like syndrome 50~150 pg/m dose, and grade II fever flue- like syndrome were observed at the dose of grater than 250 u/m(2)/d dose. Even at the 700 ug/m(2)/ d dose, no greater than grade III toxicities were observed. Leucocytosis were dose dependent with 120-480% increment of baseline. Pharmacokinetic parameters are as follows; Cmax were dose dependent(0.42-11.7 ng/ml) with 2-4 hours of Tmax. AUC were also dose dependent(3.93~87.9ng.hr/ml) with sustained serum levels(0.2-2ng/ml) up to 12 hours after rh GM-CSF administration. Urinary excretion(0-24 hours) after GM-CSF was less than 1% of administered dose. Yeast-derived rh GM-CSF induces leucocytosis in the dose range of 150~500ug/m(2)/d with tolerable side effects. Subcutaneously administered rh GM-CSF has sustained serum levels up to 12 hours after administration. The doses of 150-500 ug/m/d would be appropriated for the further trials.

2,768 View
14 Download

A Phase 2 Clinical Trial of Recombinant Human Granulocyte Macrophage Colony Stimulatin: Sun Young Rha, Jae Kyung Roh, Kyung Hee Lee, Hyun Cheol Chung, Jong Inn Lee, Jin Hyuk Choi, Hye Ran Lee, Nae Chun Yoo, Joo Hang Kim, Dae Seog Heo, Jin Hyuk Choi, Ho Yeong Lim, Jee Sook Hahn, Byung So; J Korean Cancer Assoc. 1995;27(3):490-504.

Abstract PDF: Background
; Rh GM-CSF is known to stimulate the growth of granulocyte-macrophage pre- cursors and can prevent the neutropenia and infection after high dose chemotherapy. We planned to evaluate the efficacy and toxicities of rh GM-CSF and to determine the clinically recommended dose of yeast-derived rh GM-CSF(LBD-005), based on the biologicaily active doses from phase I clinical triaL Methods; Open non-randomized phase II study was carried out in 40 cancer patients with chemotherapy induced myelosuppression. After the control period(chemotherapy without rh GM-CSF), rh GM-CSF was started 24 hours after the second chemotherapy to 3 groups of patients with the doses of 150, 250, 350 ug/m(2)/d by once-daily subcutaneous admlnistration for 10 days. Resnlts; Of the 40 enrolled patients, two patients refused to be followed and. one patient couldn't finish the study due to the disease progression. So 37 patients were evaluable and the number of patients at the dose of 150, 250, 350 pg/m/d were 12, 12 and 13 petients, respectively. They were consisted of 12 with stomach cancers, 10 with breast cancers, 5 with osteosarcoma and 10 patients with other malignancies, and received chemotherapeutic agents like VP-16, cisplatinum, adriamycin. When we compared the hematologic parameters between the control and treatment periods, the mean nadir of WBC counts(/mm(3)) at the dose of 150ug/m(2)/d were 1480, 2085, each, l280, l997 at the dose of 250 ug/m/d, and 1091, 1788 at the dose of 350 ug/m(2)/d respectively. Also the recovery days of WBC counts from nadir to 4000/m(3) were improved from 8 days in control period to 4.7 days in treatment period at the dose of 150 ug/m(2)/d. There were the same results at the dose of 250 and 350 ug/m(2)/d, such as from 7.4 days to 4.4 days and from 8.5 days to 5.2 days, respectively. In view of neutrophils, we could find the same results(p<0.05). There are trends that the recovery from nadir at the dose of 250 ug/m(2)/d or more is rapid, rather than l50ug/m(2)/d. Two patients with 350ug/m(2)/d complained of severe (WHO toxicity grade III) skin reaction and chest tightness, but they tolerated well after reduction to 250 ug/m(2) /d dose. Conclasion; This study suggested the effects of yeast-derived rh GM-CSF with the dose of 1SO, 250, 350ug/m(2)/d, S.Q. for 10 days to prvent the chemotherapy induced neutropenia. And when we considered the efficacy and tolerability, 250 ug/m(2)/d is appropriate for phase III clinical triaL

2,879 View
13 Download

A Phase 3 Clinical Trial of Recombinant Human Granulocyte - Macrophage Colony Stimulating: Kyung Hee Lee, Sun Young Rha, Jae Kyung Roh, Jong In Lee, Hae Ran Lee, Jun Oh Park, Jae Woong Cho, Hyun Cheol Chung, Joo Hang Kim, Jee Sook Hahn, Yun Woong Ko, Byung Soo Kim, Ho Young Lim, Jin Hyuk Choi; J Korean Cancer Assoc. 1995;27(5):804-816.

Abstract PDF: Background
Recombinant human granulocyte-macrophage colony stimulating factor(rhGM- CSF, LBD-005) may reduce chemotherapy induced myelosuppression, and thus reduce the incidence of neutropenic fever and infection after the dose intensive chemotherapy. In previous phase I and II studies, clinical efficacies and side effects of rhGM-CSF were evaluated, and the dose of 250ug/m(2)/day for 10 consecutive days subcutaneous administration was recommended for the further clinical triaL Methods: In this phase III trial, we evaluated the efficacy and safety of rhGM-CSF in 35 advanced cancer pstients after combination chemotherapy. Every eligible patients received at least 2 cycles of chemotherapy with the same dose and schedule. At the first cycle, control period, scheduled chemotherapy was given without rhGM-CSF, and at the second cycle, treatment period, rhGM-CSF was administered for 10 consecutive days subcutaneously with the dose of 250u/m(2)/day after the same chemotherapy given previously. During observation and treatment period, clinical and pathoiogical effects were monitered. Resnlta: All enrolled 35 patients were evaluable, and 14 patients(40%) had stomach cancer. The hematologic parameters were compared between two periods; mean nadir of WBC(neutrophil) counts during the control period and treatment period were 1,154+-485/mm(3)(241/mm(3)+ 242) and 2,486+1,554/mm(3)(912+-1,186/mm(3)) respectively(P<0.0001). Also the recovery time of neutropenia was shortened(P<0.0001). Incidence of infection and the necessities of antibiotics administration were decreased(days of antibiotics adminiatration: 7 days during control period and 10 days during treatment period). Most petients showed mild, talerable toxicities like chest tightness and general malaise, except 2 patients with the reduced dose of 150 ug/m(2)/day due to grade II toxicities of chest tightness and abdominal pain. Conclnsion: Above results suggested that the administration of rhGM-CSF after chemotherapy can reduce the degree of neutropenia and the side effects of rhGM-CSF were acceptable.

3,097 View
15 Download

First
Prev
Page of 1
Next
Last

Search